JBC Origene Your Gene Company

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M405022200 on August 27, 2004

J. Biol. Chem., Vol. 279, Issue 46, 48168-48176, November 12, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/46/48168    most recent
M405022200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, Z.
Right arrow Articles by Reed, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, Z.
Right arrow Articles by Reed, J. C.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Cellular, Biochemical, and Genetic Analysis of Mechanism of Small Molecule IAP Inhibitors*

Zhiliang Wang{ddagger}, Michael Cuddy{ddagger}, Temesgen Samuel{ddagger}, Kate Welsh{ddagger}, Aaron Schimmer{ddagger}§, Farid Hanaii{ddagger}, Richard Houghten¶, Clemencia Pinilla¶, and John C. Reed{ddagger}||

From the {ddagger}The Burnham Institute, La Jolla, California 92037 and The Torrey Pines Institute for Molecular Studies, San Diego, California 92121

XIAP is member of the IAP family of anti-apoptotic proteins and is known for its ability to bind and suppress caspase family cell death proteases. A phenylurea series of chemical inhibitors of XIAP was recently generated by our laboratories (Schimmer, A. D., Welsh, K., Pinilla, C., Bonneau, M., Wang, Z., Pedersen, I. M., Scott, F. L., Glinsky, G. V., Scudiero, D. A., Sausville, E., Salvesen, G., Nefzi, A., Ostresh, J. M., Houghten, R. A., and Reed, J. C. (2004) Cancer Cell 5, 25–35). We examined the mechanisms of action of these chemical compounds using biochemical, molecular biological, and genetic methods. Active phenylurea-based compounds dissociated effector protease caspase-3 but not initiator protease caspase-9 from XIAP in vitro and restored caspase-3 but not caspase-9 enzymatic activity. When applied to tumor cell lines in culture, active phenylurea-based compounds induced apoptosis in a rapid, concentration-dependent manner, associated with activation of cellular caspases. Apoptosis induced by active phenylurea-based compounds was blocked by chemical inhibitors of caspases, with inhibitors of downstream effector caspases displaying more effective suppression than inhibitors of upstream initiator caspases. Phenylurea-based XIAP antagonists induced apoptosis (defined by annexin V staining) prior to mitochondrial membrane depolarization, in contrast to cytotoxic anticancer drugs. Consistent with these findings, apoptosis induced by phenylurea-based compounds was not altered by genetic alterations in the expression of Bcl-2 family proteins that control mitochondria-dependent cell death pathways, including over-expression of anti-apoptotic proteins Bcl-2 or Bcl-XL and genetic ablation of pro-apoptotic proteins Bax and Bak. Conversely, conditional over-expression of an active fragment of XIAP or genetic ablation of XIAP expression altered the apoptosis doseresponse of the compounds. Altogether, these findings indicate that phenylurea-based XIAP antagonists block interaction of downstream effector caspases with XIAP, thus inducing apoptosis of tumor cell lines through a caspase-dependent, Bcl-2/Bax-independent mechanism.


Received for publication, May 5, 2004 , and in revised form, August 13, 2004.

* This work was supported by National Institutes of Health Grant CA-78040, the Prostate Cancer Foundation, and Accelerate Brain Care Cure, Inc. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Present address: Princess Margaret Hospital, Toronto M5G 2M9, Canada.

|| To whom correspondence should be addressed: The Burnham Institute, 10901 N. Torrey Pines Rd., La Jolla, CA 92037. E-mail: reedoffice{at}burnham.org.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
H.-R. Kim, G.-H. Lee, K.-C. Ha, T. Ahn, J.-Y. Moon, B.-J. Lee, S.-G. Cho, S. Kim, Y.-R. Seo, Y.-J. Shin, et al.
Bax Inhibitor-1 Is a pH-dependent Regulator of Ca2+ Channel Activity in the Endoplasmic Reticulum
J. Biol. Chem., June 6, 2008; 283(23): 15946 - 15955.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. A. G. M. Cillessen, J. C. Reed, K. Welsh, C. Pinilla, R. Houghten, E. Hooijberg, J. Deurhof, K. C. M. Castricum, P. Kortman, C. J. Hess, et al.
Small-molecule XIAP antagonist restores caspase-9 mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cells
Blood, January 1, 2008; 111(1): 369 - 375.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. A.G.M. Cillessen, C. J. Hess, E. Hooijberg, K. C.M. Castricum, P. Kortman, F. Denkers, W. Vos, M. A. van de Wiel, G. J. Schuurhuis, G. J. Ossenkoppele, et al.
Inhibition of the Intrinsic Apoptosis Pathway Downstream of Caspase-9 Activation Causes Chemotherapy Resistance in Diffuse Large B-Cell Lymphoma
Clin. Cancer Res., December 1, 2007; 13(23): 7012 - 7021.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Z. Gao, Y. Tian, J. Wang, Q. Yin, H. Wu, Y.-M. Li, and X. Jiang
A Dimeric Smac/Diablo Peptide Directly Relieves Caspase-3 Inhibition by XIAP: DYNAMIC AND COOPERATIVE REGULATION OF XIAP BY SMAC/DIABLO
J. Biol. Chem., October 19, 2007; 282(42): 30718 - 30727.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
C. A. Karikari, I. Roy, E. Tryggestad, G. Feldmann, C. Pinilla, K. Welsh, J. C. Reed, E. P. Armour, J. Wong, J. Herman, et al.
Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein
Mol. Cancer Ther., March 1, 2007; 6(3): 957 - 966.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. H. Cheung, E. C. LaCasse, and R. G. Korneluk
X-linked inhibitor of apoptosis antagonism: strategies in cancer treatment.
Clin. Cancer Res., June 1, 2006; 12(11): 3238 - 3242.
[Full Text] [PDF]


Home page
The OncologistHome page
M. S. Ricci and W.-X. Zong
Chemotherapeutic approaches for targeting cell death pathways.
Oncologist, April 1, 2006; 11(4): 342 - 357.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. Silke, T. Kratina, D. Chu, P. G. Ekert, C. L. Day, M. Pakusch, D. C. S. Huang, and D. L. Vaux
Determination of cell survival by RING-mediated regulation of inhibitor of apoptosis (IAP) protein abundance
PNAS, November 8, 2005; 102(45): 16182 - 16187.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. P. Kater, F. Dicker, M. Mangiola, K. Welsh, R. Houghten, J. Ostresh, A. Nefzi, J. C. Reed, C. Pinilla, and T. J. Kipps
Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis
Blood, September 1, 2005; 106(5): 1742 - 1748.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. C. Reed and M. Pellecchia
Apoptosis-based therapies for hematologic malignancies
Blood, July 15, 2005; 106(2): 408 - 418.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
W. S. El-Deiry
Meeting Report: The International Conference on Tumor Progression and Therapeutic Resistance
Cancer Res., June 1, 2005; 65(11): 4475 - 4484.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
U. Fischer and K. Schulze-Osthoff
New Approaches and Therapeutics Targeting Apoptosis in Disease
Pharmacol. Rev., June 1, 2005; 57(2): 187 - 215.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
B. Z. Carter, M. Gronda, Z. Wang, K. Welsh, C. Pinilla, M. Andreeff, W. D. Schober, A. Nefzi, G. R. Pond, I. A. Mawji, et al.
Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells
Blood, May 15, 2005; 105(10): 4043 - 4050.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
O. Berezovskaya, A. D. Schimmer, A. B. Glinskii, C. Pinilla, R. M. Hoffman, J. C. Reed, and G. V. Glinsky
Increased Expression of Apoptosis Inhibitor Protein XIAP Contributes to Anoikis Resistance of Circulating Human Prostate Cancer Metastasis Precursor Cells
Cancer Res., March 15, 2005; 65(6): 2378 - 2386.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
A. D. Schimmer and S. Dalili
Targeting the IAP Family of Caspase Inhibitors as an Emerging Therapeutic Strategy
Hematology, January 1, 2005; 2005(1): 215 - 219.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.